raltegravir-potassium has been researched along with Drug-Overdose* in 3 studies
3 other study(ies) available for raltegravir-potassium and Drug-Overdose
| Article | Year |
|---|---|
An HIV-infected Patient with No Serious Adverse Events after Overdosing on Raltegravir.
Patients with HIV infection represent a high-risk group for medication overdose because of the high frequency of complicating psychiatric disorders. Raltegravir is well-known for its low frequency of adverse effects. We herein report a 42-year-old Japanese man with HIV infection who was hospitalized 6 hours after overdosing with 24,000 mg of raltegravir in a suicide attempt. No serious adverse events occurred, although the plasma concentration of raltegravir at 18 hours after the overdose was 79,871.1 ng/mL. Raltegravir may be well-indicated for HIV patients at risk of overdosing. Topics: Adult; Anti-HIV Agents; Drug Overdose; HIV Infections; Humans; Male; Raltegravir Potassium | 2020 |
Were Additional Treatments Affecting the Pharmacokinetics Administered after Raltegravir Overdosing?
Topics: Anti-HIV Agents; Drug Overdose; HIV Infections; HIV Integrase Inhibitors; Humans; Raltegravir Potassium | 2020 |
Were Additional Treatments Affecting Pharmacokinetics Administered after Raltegravir Overdosing?: Authors' Reply.
Topics: Drug Overdose; HIV Infections; Humans; Raltegravir Potassium; Therapeutic Irrigation | 2020 |